Ninety One SA PTY Ltd Sells 5,206 Shares of Edwards Lifesciences Corporation $EW

Ninety One SA PTY Ltd lowered its position in Edwards Lifesciences Corporation (NYSE:EW) by 3.6% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 139,778 shares of the medical research company’s stock after selling 5,206 shares during the quarter. Edwards Lifesciences comprises 1.8% of Ninety One SA PTY Ltd’s investment portfolio, making the stock its 17th largest holding. Ninety One SA PTY Ltd’s holdings in Edwards Lifesciences were worth $10,894,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Nuveen LLC bought a new position in Edwards Lifesciences during the first quarter worth about $330,881,000. Jennison Associates LLC lifted its stake in shares of Edwards Lifesciences by 34.3% during the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock valued at $731,036,000 after buying an additional 2,576,383 shares in the last quarter. Woodline Partners LP lifted its stake in shares of Edwards Lifesciences by 7,805.0% during the 1st quarter. Woodline Partners LP now owns 825,358 shares of the medical research company’s stock valued at $59,822,000 after buying an additional 814,917 shares in the last quarter. AQR Capital Management LLC lifted its stake in shares of Edwards Lifesciences by 339.7% during the 1st quarter. AQR Capital Management LLC now owns 918,537 shares of the medical research company’s stock valued at $65,381,000 after buying an additional 709,648 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in Edwards Lifesciences by 37.0% during the 1st quarter. BNP Paribas Financial Markets now owns 1,946,818 shares of the medical research company’s stock valued at $141,105,000 after acquiring an additional 525,822 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $77.84 on Wednesday. The business’s 50-day moving average price is $78.54 and its two-hundred day moving average price is $75.84. Edwards Lifesciences Corporation has a twelve month low of $64.00 and a twelve month high of $83.00. The stock has a market cap of $45.70 billion, a P/E ratio of 11.20, a PEG ratio of 3.71 and a beta of 1.07. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company’s revenue was up 11.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, equities analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on EW shares. Canaccord Genuity Group boosted their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company a “hold” rating in a report on Friday, July 25th. Wall Street Zen cut Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research report on Monday. The Goldman Sachs Group restated a “buy” rating on shares of Edwards Lifesciences in a research note on Friday, July 25th. Robert W. Baird raised their target price on Edwards Lifesciences from $78.00 to $79.00 and gave the stock a “neutral” rating in a research note on Friday, July 25th. Finally, Truist Financial increased their price target on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the stock a “hold” rating in a report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $86.61.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider directly owned 206,900 shares of the company’s stock, valued at $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.34% of the stock is owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.